DK1553966T3 - Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf - Google Patents

Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf

Info

Publication number
DK1553966T3
DK1553966T3 DK03774615.3T DK03774615T DK1553966T3 DK 1553966 T3 DK1553966 T3 DK 1553966T3 DK 03774615 T DK03774615 T DK 03774615T DK 1553966 T3 DK1553966 T3 DK 1553966T3
Authority
DK
Denmark
Prior art keywords
polypeptides
immunogenic compositions
human papillomavirus
fusion peptides
peptides
Prior art date
Application number
DK03774615.3T
Other languages
English (en)
Inventor
Maria Cristina Cassetti
Larry Smith
Jeffrey K Pullen
Susan P Mcelhiney
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1553966T3 publication Critical patent/DK1553966T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03774615.3T 2002-10-03 2003-10-02 Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf DK1553966T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41592902P 2002-10-03 2002-10-03
PCT/US2003/031726 WO2004030636A2 (en) 2002-10-03 2003-10-02 Human papillomavirus polypeptides and immunogenic compositions

Publications (1)

Publication Number Publication Date
DK1553966T3 true DK1553966T3 (da) 2012-09-17

Family

ID=32069921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03774615.3T DK1553966T3 (da) 2002-10-03 2003-10-02 Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf

Country Status (16)

Country Link
US (2) US7223408B2 (da)
EP (1) EP1553966B1 (da)
JP (2) JP4755422B2 (da)
KR (1) KR101145190B1 (da)
CN (1) CN1720060B (da)
AU (1) AU2003282731B2 (da)
BR (1) BR0314529A (da)
CA (1) CA2499837C (da)
CO (1) CO5700784A2 (da)
DK (1) DK1553966T3 (da)
ES (1) ES2391451T3 (da)
MX (1) MXPA05003395A (da)
NZ (1) NZ556544A (da)
PT (1) PT1553966E (da)
WO (1) WO2004030636A2 (da)
ZA (1) ZA200502618B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DK1363938T3 (da) 2000-08-03 2014-03-24 Univ Johns Hopkins Molekylær vaccine, der forbinder et endoplasmisk reticulum-chaperonepolypeptid med et antigen
DK1553966T3 (da) * 2002-10-03 2012-09-17 Wyeth Corp Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
JP4474264B2 (ja) 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
US7354719B2 (en) 2004-12-08 2008-04-08 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006075245A2 (en) * 2005-01-14 2006-07-20 The Regents Of The University Of Michigan Systems, methods, and compositions for detection of human papilloma virus in biological samples
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
KR101180885B1 (ko) * 2006-04-19 2012-09-10 포항공과대학교 산학협력단 자궁경부암의 예방 및 치료를 위한 사람 파필로마바이러스폴리펩타이드와 면역 증강제를 포함하는 조성물
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
SI2162149T1 (sl) * 2007-06-01 2014-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cepivo za preprečevanje relapsa raka na dojki
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
US20120121715A1 (en) * 2008-01-02 2012-05-17 National Taiwan University DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof
EP2335730A1 (en) * 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusion polypeptides and their use for prevention and treatment of cancer
KR101197627B1 (ko) 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
JP5965846B2 (ja) * 2010-02-16 2016-08-10 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 近縁のヒトパピローマウイルス（ｈｐｖ）の血清型を検出するためのアッセイ
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
PL2604629T3 (pl) * 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
CN107723299B (zh) * 2011-10-12 2022-02-01 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的疫苗及其使用方法
US9901635B2 (en) * 2011-12-21 2018-02-27 Vaccibody As Vaccines against HPV
WO2013112549A1 (en) * 2012-01-24 2013-08-01 Sanford Research/USD Polynucleotides for treating oncogenic viral polypeptide positive tumors
CN103288931B (zh) * 2012-02-24 2015-05-27 宋硕 人类乳头瘤病毒免疫原性多肽、其制备方法及应用
EP3586870A1 (en) * 2013-03-12 2020-01-01 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
KR102523984B1 (ko) * 2014-08-15 2023-04-20 주식회사 제넥신 자궁경부 종양의 치료 방법
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
PT3283508T (pt) * 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
PL3359183T3 (pl) * 2015-10-06 2020-11-02 Invectys Konstrukty poliepitopowe do zastosowania w immunoterapii
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
EP3606549A1 (en) * 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US20220334132A1 (en) * 2019-08-08 2022-10-20 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
KR20220109444A (ko) 2020-04-24 2022-08-04 주식회사 제넥신 자궁경부암 치료방법
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6743593B2 (en) * 2000-04-05 2004-06-01 Impact Diagnostics, Inc. Immunological methodology for discerning human papillomavirus
DK1553966T3 (da) * 2002-10-03 2012-09-17 Wyeth Corp Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf

Also Published As

Publication number Publication date
EP1553966B1 (en) 2012-08-01
CO5700784A2 (es) 2006-11-30
AU2003282731A1 (en) 2004-04-23
ZA200502618B (en) 2008-10-29
EP1553966A2 (en) 2005-07-20
CA2499837A1 (en) 2004-04-15
US20070275003A1 (en) 2007-11-29
MXPA05003395A (es) 2005-06-22
JP2006501825A (ja) 2006-01-19
WO2004030636A2 (en) 2004-04-15
WO2004030636A3 (en) 2005-02-24
NZ556544A (en) 2008-11-28
PT1553966E (pt) 2012-10-22
BR0314529A (pt) 2005-08-09
CN1720060A (zh) 2006-01-11
US7378099B2 (en) 2008-05-27
ES2391451T3 (es) 2012-11-26
CA2499837C (en) 2013-12-03
KR101145190B1 (ko) 2012-05-14
KR20050053732A (ko) 2005-06-08
US20060014926A1 (en) 2006-01-19
EP1553966A4 (en) 2008-04-16
US7223408B2 (en) 2007-05-29
JP4755422B2 (ja) 2011-08-24
AU2003282731B2 (en) 2009-01-08
JP5398665B2 (ja) 2014-01-29
CN1720060B (zh) 2011-12-14
JP2010279386A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
DK1553966T3 (da) Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf
PL1673460T3 (pl) Szczepionki rekombinowane i ich zastosowanie
EP1663278A4 (en) EPO MIMETIC PEPTIDES AND FUSION PROTEINS
DK1641823T3 (da) GLP-1-analog fusionsproteiner
EP1534730A4 (en) MODIFIED TRANSFERRIN-ANTIBODY HYBRID PROTEINS
AU2002951692A0 (en) Improvements in or relating to vaccines
PL362324A1 (en) Artificial fusion proteins with reduced immunogenicity
EP1556490A4 (en) NEW NUCLEIC ACIDS AND POLYPEPTIDES
HK1083454A1 (en) Recombinant vaccine viruses expressing il-15 and methods of using the same 15(il-15)
AU2003201727A1 (en) Recombinant protein expression
AU2003272423A1 (en) Centrosome proteins and uses thereof
EP1842857A4 (en) MUTANT PROTEINS OF INTERFERON AND THEIR USE
AU2003240974A8 (en) Human prolactin antagonist-angiogenesis inhibitor fusion proteins
HK1209050A1 (en) Survivin-derived peptides and use thereof
SI1553966T1 (sl) Fuzijski peptidi, ki obsegajo polipeptida e7 in e6 človeškega papiloma virusa in imunogeni sestavki le-teh
AU2002322416A1 (en) Gfp fusion proteins and their use
GB0317376D0 (en) Immunogenic protein and uses thereof
GB0214942D0 (en) Immunogenic proteins and DNA encoding these
EP1541677A4 (en) NEW PROTEINS AND USE THEREOF
EP1577322A4 (en) NEW PROTEINS AND THEIR USE
AU2003222227A1 (en) Variant tat proteins and methods for use thereof
AU2003268252A1 (en) Tick polypeptides as anticoagulants and vaccines
EP1543120A4 (en) NEW PROTEINS AND THEIR USES
AU2003265814A8 (en) Aw755252-interacting proteins and use thereof
HK1082770A1 (en) Supter-antigen fusion proteins and the use thereof